Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

  • End date
    Sep 1, 2030
  • participants needed
  • sponsor
    Peter MacCallum Cancer Centre, Australia
Updated on 24 January 2021
stem cell transplantation
direct bilirubin
gilbert's syndrome
neutrophil count
btk inhibitor
refractory mantle cell lymphoma


This is an open label, multi-center, single-arm, phase II study investigating the efficacy and safety of the combination of ibrutinib and Tisagenlecleucel in twenty patients with relapsed or refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation.

Condition Mantle Cell Lymphoma Recurrent
Treatment ibrutinib and Tisagenlecleucel
Clinical Study IdentifierNCT04234061
SponsorPeter MacCallum Cancer Centre, Australia
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Patients must meet all the following criteria for study entry
Written informed consent prior to screening procedures
Be 18 years of age on the day of signing informed consent
Have a confirmed diagnosis of MCL according to World Health Organization (2016) criteria
Have sufficient fresh or archival material available for central review
At least one site of radiographically assessable disease not previously irradiated (lymph node with largest diameter 1.5cm, or unequivocal evaluable hepatomegaly/splenomegaly or marrow phase disease)
Meet at least one of the following disease criteria
Have relapsed, or progressed following at least 1 prior line of systemic chemoimmunotherapy for MCL (may include ibrutinib or other BTK-inhibitor in combination)
Be refractory to at least one prior line of chemoimmunotherapy (refractory is defined as less than a conventional PR following 2 cycles of anthracycline or cytarabine-containing therapy)
Have achieved <CR on PET imaging following 2 cycles of anthracycline or cytarabine-containing therapy in the presence of aberrations of p53; or <CR post autologous stem cell transplantation
Failure to achieve CR following at least 6 months of an ibrutinib or BTK inhibitor -containing front-line regimen, or failure to achieve PR following 8 weeks of a BTK inhibitor 7. Have a life expectancy of 3 months, as judged by the investigator 8. Have acceptable haematological function within 7 days prior to registration, defined as
Absolute neutrophil count 1x10^9/L (may be supported by growth)
Absolute lymphocyte count 0.3x10^9/L or absolute CD3+ fraction > 0.15x 10^9/L
Platelets >50x 10^9/L unless explained by lymphoma at the discretion of the CPI
Haemoglobin 80 g/L (may be transfusion supported) 9. Have acceptable organ function within 7 days prior to registration, defined as
Serum creatinine 1.5 x ULN, or a calculated creatinine clearance of at least 50 mL/min using the Cockcroft-Gault equation (see appendix 1) or a 24-hour urine collection
AST or ALT 3.0 x ULN
Bilirubin 1.5 x ULN (with the exception of patients with Gilbert's syndrome. Patients with Gilbert's syndrome may be included if their total bilirubin is 3.0 x ULN and direct bilirubin 1.5 x ULN)
aPTT and PT 1.5x ULN
Adequate pulmonary function defined as
No or mild dyspnea ( grade 1)
Oxygen saturation measured by pulse oximetry 90 percent on room air 10. Female patients of childbearing potential and non-sterile male patients (with partners of childbearing potential) must agree to use highly effective methods of contraception from registration on the study to 30 days after the last dose of ibrutinib and 12 months after Tisagenlecleucel infusion and until Tisagenlecleucel is no longer present by qPCR on two consecutive tests (whichever is later)
Total abstinence from sexual intercourse when this is in line with the preferred and usual life style of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks prior to registration. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment
Male sterilisation (at least 6 months prior to screening). For female patients on the study, the vasectomised male partner should be the sole partner for that patient
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before enrolment into this study
Women are considered post-menopausal and not of child bearing potential if
they have had 12 months of natural (spontaneous) amenorrhea with an
appropriate clinical profile (e.g. age appropriate history of vasomotor
symptoms) or have had surgical bilateral oophorectomy (with or without
hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In
the case of oophorectomy alone, only when the reproductive status of the woman
has been confirmed by follow-up hormone level assessment is she considered not
of child bearing potential
\. Female patients of childbearing potential must have a negative serum
(beta-human chorionic gonadotropin (-hCG) or urine pregnancy test within 7
days of registration 12. Sexually active male patients must use a condom
during intercourse and must agree to refrain from sperm donation, from
registration on the study until 30 days after the last dose of ibrutinib or 12
months after Tisagenlecleucel infusion and until Tisagenlecleucel is no longer
present by qPCR on two consecutive tests

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry
Prior allogeneic transplantation
Autologous transplantation within 6 weeks prior to registration
Active and uncontrolled autoimmune cytopenias
Active central nervous system involvement with MCL
Previous treatment with adoptive T-cell therapy
Receipt of a non BTK-inhibitor investigational medical product within the last 30 days prior to planned leukapheresis
Receipt of a non-anti CD20- monoclonal antibody with anti-neoplastic intent within 30 days prior to planned leukapheresis
Receipt of steroids >20mg prednisolone or equivalent in the fortnight prior to planned leukapheresis
Requirement for ongoing therapy with
Potent CYP3A inhibitors (e.g. indinavir, ketoconazole, clarithromycin)
Potent CYP3A inducers (e.g. rifampin, phenytoin, carbamazepine)
Vitamin K antagonists (e.g. warfarin or equivalent)
Antiretroviral medications 10. Consumption within 3 days prior to registration
Grapefruit or grapefruit products
Seville oranges
Star fruit 11. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months of screening or class III to IV cardiac disease as defined by the New York Heart Association Functional Classification 12. Active neurological disorders of clinical relevance (e.g. epilepsy, severe brain injury, dementia, Parkinson's disease or autoimmune/inflammatory disorders (e.g. Guillain-Barre syndrome, motor neurone disease, chronic inflammatory demyelinating polyneuropathy) 13. Other significant life-threatening illness or medical condition which, in the investigator's opinion, could compromise the subject's safety, interfere with absorption or metabolism of study drug, or put the study outcomes at undue risk 14. History of other active malignancy, with the exception of
Adequately treated in situ carcinoma of the cervix or breast
Adequately treated basal cell carcinoma of skin or localised squamous cell carcinoma of the skin
Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and without evidence of recurrence for at least 2 years prior to registration 15. History of human immunodeficiency (HIV) or active hepatitis C virus or active hepatitis B virus. NOTE: Serology must be repeated at the pre-conditioning stage prior to infusion with Tisagenlecleucel. 16. Clinically significant active infection confirmed by clinical evidence, imaging or positive laboratory tests (e.g. blood cultures, viral DNA/RNA by PCR) 17. Receipt of live, attenuated vaccines within 4 weeks of registration 18. Major surgery within 4 weeks prior to registration 19. Pregnant or nursing (lactating) women. Note: Women of child-bearing potential must have a negative serum pregnancy test performed within 24 hours before leukapheresis, lymphodepletion (if performed) and prior to Tisagenlecleucel infusion. 20. Known hypersensitivity to the excipients of Tisagenlecleucel or to any product to be given to the patient as per the study protocol (e.g. tocilizumab and lymphodepleting agents)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note